Michael Mack1*, MD; Anupama Vasudevan2, PhD; Mohanad Hamandi2, MD
1. Baylor Scott & White Health, Dallas, TX, USA; 2. The Heart Hospital Baylor Plano Research Center, Plano, TX, USA
Transcatheter aortic valve replacement (TAVR) has been shown to be non-inferior to surgical aortic valve replacement (SAVR) in multiple randomised trials in high- and intermediate-risk patients1-5. Most patients studied in these randomised trials were elderly, being for the most part in their late seventies and early eighties in age. Two trials in lower-risk patients which have recently completed enrolment in the USA presumably include younger patients. However, the results of those trials will not be available until mid 2019.
In this issue of EuroIntervention, Eggebrecht and colleagues have attempted to shed some light on the outcomes of TAVR ...